AnaSpec Introduces New SensoLyte™ 570 Generic MMP Assay Kit with Industry’s Highest Wavelength

6:16 pm | Albert Hong | Be the first to comment

August 7, 2008 – San Jose, CA 

Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated proteins capable of digesting extracellular matrix components. The importance of MMPs in tumor development and invasion as well as other diseases is well known.

 AnaSpec has introduced the SensoLyteTM 570 Generic MMP Assay Kit, offering the industry’s highest emission wavelength for MMP detection. The higher emission wavelength allows the SensoLyteTM 570 Generic MMP Assay Kit to offer greater sensitivity in detecting enzyme activities with minimal interference from the autofluorescence of cell components and test compounds. This kit is ideal for detecting generic MMP activity in biological samples or for high throughput screening of MMP inducers and inhibitors using purified MMPs. The SensoLyte™ 570 Generic MMP Assay Kit is optimized to detect the activity of a variety of MMPs, including MMP-1, 2, 7, 8, 9, 10, 13, and 14 (Fig.1). This kit uses a FRET peptide substrate labeled with 5-TAMRA (fluorophore) and QXL™ 570 (quencher) for continuous measurement of enzyme activities. In an intact FRET peptide, the fluorescence of 5-TAMRA is quenched by QXL™ 570. Upon the cleavage of the FRET peptide by MMPs, the fluorescence of 5-TAMRA is recovered, and can be continuously monitored at excitation/emission = 540 nm/575 nm. The assays are performed in a convenient 96-well format. 
Company Info AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions.  With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (including dyes, assay kits, and antibodies) and combinatorial chemistry. Visit www.anaspec.com for more information. 

AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies

11:20 am | Albert Hong | Be the first to comment

San Jose, CA – April 28, 2008 With experience in the synthesis of phospho-specific peptides, AnaSpec has introduced a full suite of phospho-specific ErbB-2 (Her-2) polyclonal antibodies. These phosphorylated antibodies show no cross reactivity and are specific for phospho-tyrosine at position 877, 1112, 1222 and 1248.    The HER-2/neu, also known as c-erbB2, or CD340 proto-oncogene encodes a 185-kDa transmembrane receptor protein. It has partial homology with the epidermal growth factor receptor and shares intrinsic tyrosine kinase activity with that receptor. HER2 plays a role in oncogenesis in breast, ovarian, gastric, and lung carcinoma and endocrine tumors.

HER2 is constitutively activated in the absence of ligand and signaling occurs through phosphorylation of specific tyrosine residues which serve as docking sites for the adaptor molecules SHC and GRB2 with subsequent activation of Ras-ERK and PI-3K pathways. HER2 activation of the extracellular signal-regulated kinase (ERK) pathway is primarily dependent on phosphorylation of Y1248/1253 of HER2 and mutation of this residue substantially diminishes the transforming potential of HER2. Other important phosphorylation sites of HER-2 include Y877 and Y1112. AnaSpec offers several anti-Her-2/neu (c-erbB2) antibodies developed against the phosphorylated tyrosine-containing Her-2/neu sequences, and corresponding antibodies raised to the same sequence but surrounding non-phosphorylated tyrosine.    Listing of Her-2 Antibodies:Anti - ErbB-2 (Her-2)Anti - ErbB-2 (Her-2) (pTyr877)  Anti - ErbB-2 (Her-2) (paired 877)  Anti - ErbB-2 (Her-2) (pTyr1112)  Anti - ErbB-2 (Her-2) (paired 1112)  Anti - ErbB-2 (Her-2) (pTyr1222)Anti - ErbB-2 (Her-2) (paired1222) Anti - ErbB-2 (Her-2) (pTyr1248) Anti - ErbB-2 (Her-2) (paired1248)  REFERENCES:Coussens L. et al. Science 230,1132 (1985).Cobleigh, M. et al J. Clin. Oncol. 17, 2639 (1999).Castilla-Guerra L. et al. Histopathology  31, 144 (1997).Yonemura, Y. et al. Cancer  67, 2914 (1991). 
Company InfoAnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.For more information, visit www.anaspec.com